Citations (91)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Yunxiang Ma, Junkai Wang, Changhua Wang, Qiong Zhang, Yannan Xu, Huajin Liu, Xia Xiang & Jiangwei Ma. (2019) DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells. Artificial Cells, Nanomedicine, and Biotechnology 47:1, pages 3823-3831.
Read now
Read now
Cristina M. Alcántara & Andrés R. Alcántara. (2018) Biocatalyzed synthesis of antidiabetic drugs: A review. Biocatalysis and Biotransformation 36:1, pages 12-46.
Read now
Read now
Takashi Kadowaki, Satsuki Muto, Yoshiumi Ouchi, Ryutaro Shimazaki & Yutaka Seino. (2017) Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opinion on Pharmacotherapy 18:18, pages 1903-1919.
Read now
Read now
Baptist Gallwitz. (2017) A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. Expert Opinion on Drug Safety 16:12, pages 1399-1405.
Read now
Read now
Huan Yu & Vincent C Woo. (2017) Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin. Diabetes, Metabolic Syndrome and Obesity 10, pages 317-332.
Read now
Read now
Ryuichi Morishita & Hironori Nakagami. (2015) Teneligliptin: expectations for its pleiotropic action. Expert Opinion on Pharmacotherapy 16:3, pages 417-426.
Read now
Read now
Jocelyn de Heer & Burkhard Göke. (2014) Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?. Expert Opinion on Drug Safety 13:11, pages 1469-1481.
Read now
Read now
Kimberly A Coughlan, Rudy J Valentine, Neil B Ruderman & Asish K Saha. (2014) AMPK activation: a therapeutic target for type 2 diabetes?. Diabetes, Metabolic Syndrome and Obesity 7, pages 241-253.
Read now
Read now
Articles from other publishers (83)
Lamija Ferhatbegović, Denis Mršić & Amra Macić-Džanković. (2023) The benefits of GLP1 receptors in cardiovascular diseases. Frontiers in Clinical Diabetes and Healthcare 4.
Crossref
Crossref
Züleyha Doğanyiğit, Aslı Okan, Serpil Taheri, Zeynep Yılmaz, Enes Akyüz & Necdet Demir. (2023) Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart. Chemical Biology & Drug Design 102:5, pages 1085-1096.
Crossref
Crossref
Osama F. Elabi, Dimitra Karampatsi, Ellen Vercalsteren, Grazyna Lietzau, Thomas Nyström, Thomas Klein, Vladimer Darsalia, Cesare Patrone & Gesine Paul. (2023) DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes–Induced Blood–Brain Barrier Leakage and Normalize Capillary Pericyte Coverage. Diabetes 72:3, pages 405-414.
Crossref
Crossref
Harald Tammen, Martin Kömhoff, Denis Delić, Søren S. Lund, Berthold Hocher, Sandra Frankenreiter, Rüdiger Hess, Maximilian von Eynatten, Michael Mark & Thomas Klein. (2023) Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans. Scientific Reports 13:1.
Crossref
Crossref
Grazyna Lietzau, Stelia Ntika, Hiranya Pintana, Linda Tracy, Thomas Klein, Thomas Nyström, Vladimer Darsalia, Cesare Patrone & Camilla Krizhanovskii. (2021) A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia. Cellular and Molecular Neurobiology 42:6, pages 1995-2002.
Crossref
Crossref
Won Kyeong Jeon, Jeehoon Kang, Hyo-Soo Kim & Kyung Woo Park. (2022) Correction to: “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”. Journal of Lipid and Atherosclerosis 11:1, pages 89.
Crossref
Crossref
Kristin Gonzales & Adrian Vella. 2021. Clinical Dilemmas in Diabetes. Clinical Dilemmas in Diabetes
146
160
.
Alessia Maria Calabrese, Valeria Calsolaro, Sara Rogani, Chukwuma Okoye, Nadia Caraccio & Fabio Monzani. (2021) Optimal Type 2 Diabetes Mellitus Management and Active Ageing. Endocrines 2:4, pages 523-539.
Crossref
Crossref
Marwa Mohsen, Ahmed A. Elberry, Alaa Mohamed Rabea, Mohamed E. A. Abdelrahim & Raghda R. S. Hussein. (2021) Recent therapeutic targets in diabetic nephropathy. International Journal of Clinical Practice 75:11.
Crossref
Crossref
Zhenhong Pan, Yan Yang & Jingjing Zhang. (2020) Efficacy and safety of DPP‐IV inhibitors combined with basal insulin in the treatment of type 2 diabetes. Journal of Diabetes 13:5, pages 375-389.
Crossref
Crossref
E. V. Biryukova, I. A. Morozova & S. V. Rodionova. (2021) Type 2 diabetes: evidence-based medicine approach to glucose-lowering therapy. Meditsinskiy sovet = Medical Council:21, pages 160-168.
Crossref
Crossref
Won Kyeong Jeon, Jeehoon Kang, Hyo-Soo Kim & Kyung Woo Park. (2021) Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis. Journal of Lipid and Atherosclerosis 10:2, pages 210.
Crossref
Crossref
Qian Zhang, Xinhua Xiao, Jia Zheng, Ming Li, Miao Yu, Fan Ping, Tong Wang & Xiaojing Wang. (2020) Maternal sitagliptin treatment attenuates offspring glucose metabolism and intestinal proinflammatory cytokines IL-6 and TNF-α expression in male rats. PeerJ 8, pages e10310.
Crossref
Crossref
Quan Zhang, Haiqiang Dou & Patrik Rorsman. (2020)
‘Resistance is futile?’ – paradoxical inhibitory effects of K
ATP
channel closure in glucagon‐secreting α‐cells
. The Journal of Physiology 598:21, pages 4765-4780.
Crossref
Crossref
Ingrid Lovise Augestad, Hiranya Pintana, Martin Larsson, Camilla Krizhanovskii, Thomas Nyström, Thomas Klein, Vladimer Darsalia & Cesare Patrone. (2020) Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery. Diabetes 69:9, pages 1961-1973.
Crossref
Crossref
R. D. Carr & A. Solomon. (2020) Inhibitors of dipeptidyl peptidase‐4 as therapeutic agents for individuals with type 2 diabetes: a 25‐year journey. Diabetic Medicine 37:8, pages 1230-1233.
Crossref
Crossref
Melanie J. Davies, Cristina Bianchi & Stefano Del Prato. (2020) Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. Metabolism 107, pages 154242.
Crossref
Crossref
Grazyna Lietzau, Giulia Magni, Jan Kehr, Takashi Yoshitake, Emanuel Candeias, Ana I. Duarte, Hans Pettersson, Josefin Skogsberg, Maria P. Abbracchio, Thomas Klein, Thomas Nyström, Stefania Ceruti, Vladimer Darsalia & Cesare Patrone. (2020) Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging. Neurobiology of Aging 89, pages 12-23.
Crossref
Crossref
Ehsan Rahimy, Keith Baker, Desmond Thompson & Namrata Saroj. (2020) Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema. Ophthalmic Surgery, Lasers and Imaging Retina 51:4, pages 226-234.
Crossref
Crossref
Burak Yulug, Ozlem Saatci, Aysun Işıklar, Lutfu Hanoglu, Ulkan Kilic, Mehmet Ozansoy, Seyda Cankaya, Baris Cankaya & Ertugrul Kilic. (2020) The Association between HbA1c Levels, Olfactory Memory and Cognition in Normal, Pre-Diabetic and Diabetic Persons. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:2, pages 198-212.
Crossref
Crossref
Courtney Ackeifi, Peng WangEsra KarakoseJocelyn E. Manning FoxBryan J. González, Hongtao LiuJessica Wilson, Ethan SwartzCecilia BerrouetYansui LiKunal KumarPatrick E. MacDonald, Roberto SanchezBernard ThorensRobert DeVita, Dirk Homann, Dieter EgliDonald K. Scott, Adolfo Garcia-Ocaña & Andrew F. Stewart. (2020) GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration. Science Translational Medicine 12:530.
Crossref
Crossref
Jens Juul Holst. (2020) Incretin therapy for diabetes mellitus type 2. Current Opinion in Endocrinology, Diabetes & Obesity 27:1, pages 2-10.
Crossref
Crossref
L.V. Zhuravlyova & M.V. Filonenko. (2020) The role of dipeptidylpeptidase-4 inhibitors in the current therapy of type 2 diabetes mellitus. Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini 2020:2, pages 80-84.
Crossref
Crossref
Ioanna Markaki, Kristian Winther, Sergiu-Bogdan Catrina & Per Svenningsson. 2020. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases
91
112
.
Sara L. Jepsen, Kaare V. Grunddal, Nicolai J. Wewer Albrechtsen, Maja S. Engelstoft, Maria B. N. Gabe, Elisa P. Jensen, Cathrine Ørskov, Steen S. Poulsen, Mette M. Rosenkilde, Jens Pedersen, Fiona M. Gribble, Frank Reimann, Carolyn F. Deacon, Thue W. Schwartz, Andreas D. Christ, Rainer E. Martin & Jens J. Holst. (2019) Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice. American Journal of Physiology-Endocrinology and Metabolism 317:6, pages E1081-E1093.
Crossref
Crossref
Jens J. Holst, Nicolai J. Wewer Albrechtsen, Mette M. Rosenkilde & Carolyn F. Deacon. 2011. Comprehensive Physiology. Comprehensive Physiology
1339
1381
.
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyoungmin Kim & Kwan Woo Lee. (2019) Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report. Diabetes Therapy 10:4, pages 1271-1282.
Crossref
Crossref
Baptist Gallwitz. (2019) Clinical Use of DPP-4 Inhibitors. Frontiers in Endocrinology 10.
Crossref
Crossref
Jasmin & Vikas Jaitak. (2019) A Review on Molecular Mechanism of Flavonoids as Antidiabetic Agents. Mini-Reviews in Medicinal Chemistry 19:9, pages 762-786.
Crossref
Crossref
Andrew Whang, Ravinder Nagpal & Hariom Yadav. (2019) Bi-directional drug-microbiome interactions of anti-diabetics. EBioMedicine 39, pages 591-602.
Crossref
Crossref
Grazyna Lietzau, William Davidsson, Claes-Göran Östenson, Fausto Chiazza, David Nathanson, Hiranya Pintana, Josefin Skogsberg, Thomas Klein, Thomas Nyström, Vladimer Darsalia & Cesare Patrone. (2018) Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin. Acta Neuropathologica Communications 6:1.
Crossref
Crossref
Fausto Chiazza, Harald Tammen, Hiranya Pintana, Grazyna Lietzau, Massimo Collino, Thomas Nyström, Thomas Klein, Vladimer Darsalia & Cesare Patrone. (2018) The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway. Cardiovascular Diabetology 17:1.
Crossref
Crossref
Marco Bugliani, Farooq Syed, Flavia M.M. Paula, Bilal A. Omar, Mara Suleiman, Sandra Mossuto, Francesca Grano, Francesco Cardarelli, Ugo Boggi, Fabio Vistoli, Franco Filipponi, Paolo De Simone, Lorella Marselli, Vincenzo De Tata, Bo Ahren, Decio L. Eizirik & Piero Marchetti. (2018) DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes. Molecular and Cellular Endocrinology 473, pages 186-193.
Crossref
Crossref
Kurt Ritter. 2003. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry
1
37
.
Sang Youb Han, Sun Ae Yoon, Byoung Geun Han, Sung Gyun Kim, Young‐Il Jo, Kyung Hwan Jeong, Kook‐Hwan Oh, Hyeong Cheon Park, Sun‐Hee Park, Shin‐Wook Kang, Ki‐Ryang Na, Sun Woo Kang, Nam‐Ho Kim, Younghwan Jang, Bogyeong Kim, Seonghye Shin & Dae Ryong Cha. (2017) Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study. Diabetes, Obesity and Metabolism 20:2, pages 292-300.
Crossref
Crossref
Carolyn F. Deacon. (2018) Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes. Peptides 100, pages 150-157.
Crossref
Crossref
Md. Akil Hossain & Rokeya Pervin. 2018. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome
455
473
.
Cristina Bianchi, Giuseppe Daniele, Angela Dardano & Stefano Del Prato. 2018. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
527
569
.
Cristina Bianchi, Giuseppe Daniele, Angela Dardano & Stefano Del Prato. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
44
.
Leah Boyle, Rebecca Grainger, Rosemary M Hall & Jeremy D Krebs. (2017) Use of and Beliefs About Mobile Phone Apps for Diabetes Self-Management: Surveys of People in a Hospital Diabetes Clinic and Diabetes Health Professionals in New Zealand. JMIR mHealth and uHealth 5:6, pages e85.
Crossref
Crossref
Daisuke Yabe, Takashi Eto, Masanari Shiramoto, Shin Irie, Kenta Murotani, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose, Susumu Seino, Bo Ahrén & Yutaka Seino. (2017) Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes, Obesity and Metabolism 19:3, pages 442-447.
Crossref
Crossref
Lesley J. Scott. (2017) Sitagliptin: A Review in Type 2 Diabetes. Drugs 77:2, pages 209-224.
Crossref
Crossref
Yuka Ito, Masahiko Mori, Yuki Matsumoto & Taro Okamoto. (2017) Pharmacological action and clinical results of Omarigliptin (MARIZEV<sup>®</sup> tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes. Folia Pharmacologica Japonica 149:3, pages 128-137.
Crossref
Crossref
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
512
555
.
Yoo-Ri Chung, Sung Wook Park, Jong Wan Kim, Jeong Hun Kim & Kihwang Lee. (2016) PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES. Retina 36:12, pages 2357-2363.
Crossref
Crossref
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen & Ji Hu. (2016) The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 121, pages 184-191.
Crossref
Crossref
Robert L. PageIIII, Cindy L. O’Bryant, Davy Cheng, Tristan J. Dow, Bonnie Ky, C. Michael Stein, Anne P. Spencer, Robin J. Trupp & JoAnn Lindenfeld. (2016) Drugs That May Cause or Exacerbate Heart Failure. Circulation 134:6.
Crossref
Crossref
C. F. Deacon & H. E. Lebovitz. (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 18:4, pages 333-347.
Crossref
Crossref
Harsh Panwar, Danielle Calderwood, Irene R. Grant, Sunita Grover & Brian D. Green. (2015) Lactobacilli possess inhibitory activity against dipeptidyl peptidase-4 (DPP-4). Annals of Microbiology 66:1, pages 505-509.
Crossref
Crossref
Minhua Fan, Yuelan Li & Shihong Zhang. (2016) Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus. Medicine 95:2, pages e2386.
Crossref
Crossref
Anna Solini, Chiara Rossi, Emiliano Duranti, Stefano Taddei, Andrea Natali & Agostino Virdis. (2016) Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase. Vascular Pharmacology 76, pages 62-71.
Crossref
Crossref
Kasey E. Williams, Martha C. Washington, Tanisha Johnson-Rouse, Ruth E. Johnson, Corren Freeman, Chris Reed, John Heath & Ayman I. Sayegh. (2016) Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats. Appetite 96, pages 254-259.
Crossref
Crossref
Kathleen M. Dungan. 2016. Endocrinology: Adult and Pediatric. Endocrinology: Adult and Pediatric
839
853.e2
.
Daniel J. Drucker. 2016. Endocrinology: Adult and Pediatric. Endocrinology: Adult and Pediatric
586
597.e5
.
Carolyn F Deacon. 2016. Handbook of Incretin-based Therapies in Type 2 Diabetes. Handbook of Incretin-based Therapies in Type 2 Diabetes
45
60
.
Jens Juul Holst. 2016. Handbook of Incretin-based Therapies in Type 2 Diabetes. Handbook of Incretin-based Therapies in Type 2 Diabetes
11
30
.
Petra Augstein, Gaetano Naselli, Thomas Loudovaris, Wayne J. Hawthorne, Peter Campbell, Esther Bandala-Sanchez, Kelly Rogers, Peter Heinke, Helen E. Thomas, Thomas W. Kay & Leonard C. Harrison. (2015) Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells. Diabetes Research and Clinical Practice 110:3, pages 291-300.
Crossref
Crossref
Makoto Shigeto, Reshma Ramracheya, Andrei I. Tarasov, Chae Young Cha, Margarita V. Chibalina, Benoit Hastoy, Koenraad Philippaert, Thomas Reinbothe, Nils Rorsman, Albert Salehi, William R. Sones, Elisa Vergari, Cathryn Weston, Julia Gorelik, Masashi Katsura, Viacheslav O. Nikolaev, Rudi Vennekens, Manuela Zaccolo, Antony Galione, Paul R.V. Johnson, Kohei Kaku, Graham Ladds & Patrik Rorsman. (2015) GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. Journal of Clinical Investigation 125:12, pages 4714-4728.
Crossref
Crossref
Aline Haas de Mello, Morgana Prá, Larissa Colonetti Cardoso, Rosiane de Bona Schraiber & Gislaine Tezza Rezin. (2015) Incretin-based therapies for obesity treatment. Metabolism 64:9, pages 967-981.
Crossref
Crossref
V. Altabas & K. Altabas. (2015) DPP-4 inhibition improves a sexual condition?. Medical Hypotheses 85:2, pages 124-126.
Crossref
Crossref
Basem M. Mishriky, Doyle M. Cummings & Robert J. Tanenberg. (2015) The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 109:2, pages 378-388.
Crossref
Crossref
M. D. Sharma. (2015) Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism 17:7, pages 616-621.
Crossref
Crossref
R. Charlotte Moffett, Srividya Vasu & Peter R. Flatt. (2015) Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice. Biochimica et Biophysica Acta (BBA) - General Subjects 1850:6, pages 1206-1214.
Crossref
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Crossref
Darleen A. Sandoval & David A. D'Alessio. (2015) Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease. Physiological Reviews 95:2, pages 513-548.
Crossref
Crossref
V. A. Gault, R. Lennox & P. R. Flatt. (2015) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes, Obesity and Metabolism 17:4, pages 403-413.
Crossref
Crossref
D. Yabe, H. Kuwata, M. Kaneko, C. Ito, R. Nishikino, K. Murorani, T. Kurose & Y. Seino. (2014)
Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of
DPP
‐4 inhibitors with other oral antidiabetic drugs
. Diabetes, Obesity and Metabolism 17:4, pages 430-434.
Crossref
Crossref
Matthias Eckhardt, Thomas Klein, Herbert Nar & Sandra Thiemann. 2015. Successful Drug Discovery. Successful Drug Discovery
129
156
.
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes & Flávio Reis. (2015) The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?. Journal of Diabetes Research 2015, pages 1-28.
Crossref
Crossref
Erin E. Mulvihill & Daniel J. Drucker. (2014) Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors. Endocrine Reviews 35:6, pages 992-1019.
Crossref
Crossref
Toshiyuki Hibuse, Norikazu Maeda, Ken Kishida, Takekazu Kimura, Tomoko Minami, Eriko Takeshita, Ayumu Hirata, Yasuhiko Nakagawa, Susumu Kashine, Akemi Oka, Masumi Hayashi, Hitoshi Nishizawa, Tohru Funahashi & Iichiro Shimomura. (2014) A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study. Cardiovascular Diabetology 13:1.
Crossref
Crossref
Haoda FuBradley H. CurtisDara P. SchusterAndreas FestaDavid M. Kendall. (2014) Treatment Patterns Among Older Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study. Diabetes Technology & Therapeutics 16:12, pages 833-839.
Crossref
Crossref
Baptist Gallwitz. (2014) Extra-pancreatic effects of incretin-based therapies. Endocrine 47:2, pages 360-371.
Crossref
Crossref
T. M. E. Davis. (2014) Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes, Obesity and Metabolism 16:10, pages 891-899.
Crossref
Crossref
Y. G. Kim, S. Hahn, T. J. Oh, K. S. Park & Y. M. Cho. (2014) Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism 16:10, pages 900-909.
Crossref
Crossref
Kate McKeage. (2014) Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:16, pages 1927-1946.
Crossref
Crossref
Bilal Omar & Bo Ahrén. (2014) Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors. Diabetes 63:7, pages 2196-2202.
Crossref
Crossref
Gillian M. Keating. (2014) Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74:5, pages 587-610.
Crossref
Crossref
Kenji Namoto, Finton Sirockin, Nils Ostermann, Francois Gessier, Stefanie Flohr, Richard Sedrani, Bernd Gerhartz, Jörg Trappe, Ulrich Hassiepen, Alokesh Duttaroy, Suzie Ferreira, Jon M. Sutton, David E. Clark, Garry Fenton, Mandy Beswick & Daniel K. Baeschlin. (2014) Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV. Bioorganic & Medicinal Chemistry Letters 24:3, pages 731-736.
Crossref
Crossref
Greg L. Plosker. (2014) Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:2, pages 223-242.
Crossref
Crossref
Seung-Hwan Lee. (2014)
Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (
Diabetes Metab J
2014;38:211-9)
. Diabetes & Metabolism Journal 38:4, pages 317.
Crossref
Crossref
Sang-Uk Kang. (2013) GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. Drug Discovery Today 18:23-24, pages 1309-1315.
Crossref
Crossref
C. Hasslacher. (2013) Antidiabetische Therapie bei NiereninsuffizienzAntidiabetic therapy and renal insufficiency. Der Diabetologe 9:8, pages 613-621.
Crossref
Crossref